• Explore /
  • Poster
  • / Healthcare costs associated with first-line (1L) treatment of patients with locally advanced or metastatic urothelial carcinoma (la/mUC) in the United States (US).

Healthcare costs associated with first-line (1L) treatment of patients with locally advanced or metastatic urothelial carcinoma (la/mUC) in the United States (US).

Abstract Poster

Authors

null

Chiemeka Ike

North America Evidence & Value Development, EMD Serono, Rockland, MA

Chiemeka Ike, Thitima Kongnakorn, Eszter Tichy, Agnes Benedict, Javier Sanchez Alvarez, Mairead Kearney

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship

Sub Track

Cost and Cost-Effectiveness of Care

Citation

JCO Oncol Pract 19, 2023 (suppl 11; abstr 11)

DOI

10.1200/OP.2023.19.11_suppl.11

Abstract #

11

Poster Bd #

A6

Abstract Disclosures

Similar Posters

First Author: Syed Arsalan Ahmed Naqvi

First Author: Michael Seth Weinfeld

First Author: Terence W. Friedlander

First Author: Jonathan E. Rosenberg